Do you want to read an article? Please log in or register.
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
Multiple Myeloma (MM)
Related content
Multiple Myeloma (MM)
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis
Eur J Haematol.
Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J
doi: 10.1111/ejh.12903.
Multiple Myeloma (MM)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Lancet Oncol.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD
doi: 10.1016/S1470-2045(19)30788-0.
COMMENTED
Multiple Myeloma (MM)
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
★ 1
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1016/S2352-3026(20)30070-3.
COMMENTED
Multiple Myeloma (MM)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
★ 2
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
Lancet.
Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ
doi: 10.1016/S0140-6736(20)30734-0.
Multiple Myeloma (MM)
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Lancet Haematol.
Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S
doi: 10.1016/S2352-3026(20)30081-8.
SPECIAL REPORT
Multiple Myeloma (MM)
Traitement du myélome multiple récidivant/réfractaire
Relapsed/Refractory Multiple Myeloma
Dimopoulos et al. Elotuzumab plus pomalidomide/Dexamethasone (EPd) vs Pd for treatment of relapsed/refractory multiple myeloma (RRMM): Results from the phase 2, randomized open-label ELOQUENT-3 study. EHA Annual Congress. Abstract LB2606. Obtained from the EHA website http://www.ehaweb.org
Multiple Myeloma (MM)
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Lancet Haematol.
Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Röllig C, Weisel K, Winderlich M, Griese J, Härtle S, Weirather J, Jarutat T, Peschel C, Chatterjee M
doi: 10.1016/S2352-3026(19)30249-2.
RECOMMENDED
Multiple Myeloma (MM)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Lancet Oncol.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M, OPTIMISMM trial investigators.
doi: 10.1016/S1470-2045(19)30152-4.